M&A / Deals

• M&A / Deals

Solstice Oncology secures $225m to drive porustobart’s development for cancer

pharminent September 10, 2026

• M&A / Deals

UK’s Claret Capital raises 575m for European biotechs

pharminent September 7, 2026

• M&A / Deals

GSK wagers up to $1.3B on a different kind of cancer drug

pharminent September 3, 2026

• M&A / Deals

Boehringer signs AI drug discovery deal with Owkin

pharminent September 3, 2026

• M&A / Deals

Novartis signs $3.2bn drug delivery deal with Alteogen

pharminent September 3, 2026

• M&A / Deals

Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology

pharminent September 2, 2026

• M&A / Deals

Lilly adds to immune drug pipeline with $2.9B Merida buyout

pharminent August 31, 2026

• M&A / Deals

Acquisitive Lilly offers $2.88bn for Merida Bio

pharminent August 31, 2026

• M&A / Deals

Metsera backers establish new biotech armed with China-licensed immunology asset

pharminent August 26, 2026

• M&A / Deals

McKesson to acquire Precision Medicine Group for $2.25bn

pharminent August 26, 2026

• M&A / Deals

China’s Haisco forms immunology biotech with up to $1.5B from American VCs

pharminent August 25, 2026

• M&A / Deals

Roche commits to lean-mass preservation with Hanmi obesity deal

pharminent August 24, 2026

• M&A / Deals

BioMarin spends up to $490m for Alesta’s bone disease candidate

pharminent August 19, 2026

• M&A / Deals

J&J hands lymphoma bispecific CAR T back to AbelZeta

pharminent August 17, 2026

• M&A / Deals

Novo Nordisk and AWS form AI partnership to speed drug discovery

pharminent August 17, 2026

• M&A / Deals

Sandoz targets industry patent void with $322m Henlius deal

pharminent August 17, 2026

• M&A / Deals

PTC takes a chance on Sangamo’s Fabry disease gene therapy

pharminent August 13, 2026

• M&A / Deals

Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset

pharminent August 12, 2026

• M&A / Deals

Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront

pharminent August 11, 2026

• M&A / Deals

Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments

pharminent August 7, 2026

• M&A / Deals

Supernus and Indivior merge to create scaled, CNS-focused entity

pharminent August 4, 2026

• M&A / Deals

Pathos AI signs two cancer deals with Alphamab and AZ

pharminent August 4, 2026

• M&A / Deals

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs

pharminent August 3, 2026

• M&A / Deals

Curium strikes $8bn deal to buy radiopharma rival Lantheus

pharminent August 3, 2026

• M&A / Deals

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

pharminent July 31, 2026

• M&A / Deals

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

pharminent July 29, 2026

• M&A / Deals

Argenx signs agreement to buy Forte Biosciences for $2.2bn

pharminent July 28, 2026

• M&A / Deals

Argenx deepens immuno expertise with $2.2B Forte Biosciences buy

pharminent July 27, 2026

• M&A / Deals

Repligen builds in cell therapy with $1.5bn BioLife takeover

pharminent July 22, 2026

• M&A / Deals

Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics

pharminent July 20, 2026

• M&A / Deals

Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal

pharminent July 20, 2026

• M&A / Deals

Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover

pharminent July 16, 2026

• M&A / Deals

Spero snaps up Innovent immunology drug in strategic pivot

pharminent July 14, 2026

• M&A / Deals

AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B

pharminent July 14, 2026

• M&A / Deals

Novartis and Chai Discovery collaborate on antibody identification

pharminent July 14, 2026

• M&A / Deals

Bayer banks 3bn in Apollo contraceptives division deal

pharminent July 10, 2026

• M&A / Deals

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

pharminent July 10, 2026

• M&A / Deals

GSK ends dementia alliance with Alector after setbacks

pharminent July 9, 2026

• M&A / Deals

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

pharminent July 8, 2026

• M&A / Deals

AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical

pharminent July 8, 2026